BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 15472782)

  • 1. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine for attention deficit/hyperactivity disorder.
    Garces K
    Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
    Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
    Barton J
    Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i26-9. PubMed ID: 15665154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
    Eiland LS; Guest AL
    Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
    Wernicke JF; Kratochvil CJ
    J Clin Psychiatry; 2002; 63 Suppl 12():50-5. PubMed ID: 12562062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Harrington MJ; Burke WJ
    Expert Opin Pharmacother; 2003 Jul; 4(7):1165-74. PubMed ID: 12831341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
    J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.
    Adler L; Dietrich A; Reimherr FW; Taylor LV; Sutton VK; Bakken R; Allen AJ; Kelsey D
    Ann Clin Psychiatry; 2006; 18(2):107-13. PubMed ID: 16754416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
    Adler LA; Spencer TJ; Williams DW; Moore RJ; Michelson D
    J Atten Disord; 2008 Nov; 12(3):248-53. PubMed ID: 18448861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.